MIM
CERE

MetLife Investment Management’s Cerevel Therapeutics Holdings, Inc. Common Stock CERE Stock Holding History

MetLife Investment Management’s Portfolio CERE Stock Details CERE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-4,432
Closed -$181K – 2915
2024
Q2 		$181K Sell
4,432
-32,096
-88% -$1.34M ﹤0.01% 2315
2024
Q1 		$1.54M Sell
36,528
-254
-0.7% -$10.7K 0.01% 1068
2023
Q4 		$1.56M Buy
36,782
+3,996
+12% +$115K 0.01% 1068
2023
Q3 		$716K Hold
32,786
– – 0.01% 1417
2023
Q2 		$1.04M Buy
32,786
+2,367
+8% +$72.6K 0.01% 1247
2023
Q1 		$742K Hold
30,419
– – 0.01% 1398
2022
Q4 		$959K Buy
30,419
+1,578
+5% +$44.5K 0.01% 1233
2022
Q3 		$815K Hold
28,841
– – 0.01% 1295
2022
Q2 		$763K Buy
28,841
+3,683
+15% +$105K 0.01% 1367
2022
Q1 		$881K Buy
25,158
+9,285
+58% +$271K 0.01% 1411
2021
Q4 		$515K Hold
15,873
– – ﹤0.01% 1491
2021
Q3 		$468K Hold
15,873
– – ﹤0.01% 1555
2021
Q2 		$407K Buy
+15,873
New +$227K ﹤0.01% 1695

Other funds holding CERE

IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
BTI
Blue Trust Inc Alpharetta, Georgia $9.54B AUM 19.86% 1-Year Est. Return

MetLife Investment Management's CERE Position: Q3 2024 in Review

MetLife Investment Management sold out of Cerevel Therapeutics Holdings, Inc. Common Stock (CERE) in Q3 2024, closing a stake of 4,432 shares — an estimated $181K sold.

MetLife Investment Management first reported a position in CERE in Q2 2021 and held it in 13 quarters. The position peaked at $1.56M in Q4 2023. 2 funds tracked by Wall St. Rank hold CERE as of Q3 2024.

  • MetLife Investment Management reported no remaining Cerevel Therapeutics Holdings, Inc. Common Stock position as of Q3 2024 after selling out during the quarter.
  • MetLife Investment Management sold 4,432 Cerevel Therapeutics Holdings, Inc. Common Stock shares in Q3 2024, an estimated $181K.
  • MetLife Investment Management first reported a position in Cerevel Therapeutics Holdings, Inc. Common Stock in Q2 2021 and held it in 13 quarters.
  • MetLife Investment Management's Cerevel Therapeutics Holdings, Inc. Common Stock position peaked at $1.56M in Q4 2023.
  • 2 funds tracked by Wall St. Rank held Cerevel Therapeutics Holdings, Inc. Common Stock as of Q3 2024.

Based on MetLife Investment Management's 13F filing for Q3 2024, filed 13 Nov 2024.